Summary We attempted to characterize the motivation, comprehension and expectations of patients who had given informed consent to participate in phase I trials of anti-cancer agents at the National Cancer Center of Japan. Thirty-three patients were given a simple multiplechoice questionnaire and asked to return it at a later date. The completed survey was returned by 32 patients. The patients were surveyed before they had received any investigational phase agents. Nineteen per cent of patients were motivated to participate in the phase trials by the possibility of therapeutic benefit, 9% because participation seemed a better choice than no treatment and only 6% for altruistic reasons. Most patients comprehended the major features of a phase trial, namely its investigational nature, the unknown effects of the agent investigated and the unclear benefit to the patients themselves. Fifty-nine per cent of the patients anticipated that they might suffer severe or life-threatening side-effects if they participated in the phase trial, and 43% were able to indicate accurately the purpose of the phase trial as a dose determination study. Although only a minority of the patients indicated that their motivation to participate was possible treatment benefit to themselves, when answering questions regarding expectations, more than half indicated that there might be personal benefits of varying degrees by participation.
The primary goals of phase I clinical trials for anti-cancer agents are to determine toxicity, maximum tolerated dose and recommended dose for the phase II study, as well as pharmacological evaluation of the new drug (Simon, 1993) . Preliminary evaluation of anti-tumour activity may also be included in phase I clinical trials.
A phase I clinical trial is the initial trial in human subjects of a new agent. Although healthy volunteers are appropriate candidates for phase I trials, this generalization does not apply to phase I trials of anti-cancer agents because of the side-effects and narrow therapeutic window. Anti-cancer agents in phase I trials should always be administered to patients with incurable cancer with the expectation of some therapeutic benefit. Accordingly, it is not surprising that toxicity and possible benefits of such agents are often unknown, even when there is promising preclinical data. In addition, in phase I trials, early cohorts of patients are treated at very low and sometimes ineffective dosages. The overall response rate in phase I trials is low (Estey et al, 1986; Decoster et al, 1990; Von Hoff and Turner, 1991; Penta et al, 1992; Itoh et al, 1994) . Furthermore, physicians as investigators conducting phase I trials of anti-cancer agents must always be vigilant in safeguarding the patients' best interests when confronted with ethical issues (e.g. benefit vs toxicity), and, moreover, obtaining truly informed consent is difficult (Lipsett, 1982; Ratain et al, 1993; Emanuel, 1995) .
Although almost all investigators and institutional review boards agree as to the importance of informed consent (Kodish et al, 1992) and the guiding concept in ethical clinical research is informed consent, which is meant to guarantee the voluntary Received 31 May 1996 Revised 25 November 1996 Accepted 11 December 1996 Correspondence to: K Itoh nature of participation in clinical trials, there have been only a few reports from the viewpoint of the patients in phase I clinical trials of anti-cancer agents (Rodenhuis et al, 1984; Tomamichel et al, 1995; Daugherty et al, 1995) . Furthermore, it is of interest to learn whether the patients' perception of these studies in Japan differs from that of patients in the United States and Europe. We administered a questionnaire to 33 consecutive patients who had given informed consent to participate in a phase I trial of anti-cancer agents at the National Cancer Center Hospital East in an attempt to characterize their motivation, comprehension and expectations.
PATIENTS AND METHODS
The subjects were 33 patients with advanced or metastatic cancer who had given informed consent consecutively to participate in one of three phase I trials (9) 7 (22) 9 (28) 19 (73) 1 (4) 6 (23) 28 (90) 0 (0) 3 (10) aAlthough patients were instructed to select the single most important reason, some patients selected more than one reason. 
Comprehension
The patients' comprehension of the basic features of the phase I trial is shown in Table 4 . Most of the patients indicated that they understood all (10%) or almost all (71%) of the information provided about the trial in which they would participate, and 93% indicated that they could understand the explanation given by their doctors. Most patients comprehended the basic nature of a phase I trial of anti-cancer agents in that it is an investigation of a drug of unknown effect and of unclear benefit to the patients themselves. Nineteen patients (59%) anticipated that they might suffer severe 
General conditions of informed consent
The general conditions of informed consent, which included the right to withdraw from the trial and the right to therapeutic choice, were comprehended by most patients (Table 6 ).
DISCUSSION
Informed consent by participating patients is a fundamental concept in any clinical study but especially in phase I clinical trials of anti-cancer agents, because there exist some ethical impediments in these trials (Ratain et al, 1993; Kodish et al, 1992) . These trials represent the first application of the given agent in human subjects; moreover, in addition to the unknown toxicities as well as uncertain effects, any benefits to the patient are uncertain. Thus, participants must receive very thorough and precise information conceming the trial's objectives, methods and potential risks, and even conceming the potential future benefit of the study (Tobias and Houghton, 1994) .
The results of our survey show that all patients were aware of taking part in a clinical research project and almost all understood that risks were unknown and benefits uncertain. Moreover, more than half anticipated the possibility of severe side-effects through their participation. Therefore, most patients thoroughly understood the major issues of phase I trials after being informed of the potential risks and benefits of the treatment. The possibility of treatment-related risks and side-effects are well recognized after informed consent is given even by patients in phase II1III studies (Penman et al, 1984) . It should be emphasized that these results are in accord with those found in a study in the United States (Daugherty et al, 1995) . Almost all patients in our institution seemed to have understood the voluntary nature of participation in phase I trials. However, about half did not appear to understand the purpose of phase I trials completely, with 23% indicating that the purpose was to observe side-effects. This could be regarded as an insufficient rather than an erroneous answer, as the questions in our study were multiple choice. The statement 'screening for antitumour activity' was added as a possible response for the purpose of phase I trials, because screening of anti-tumour activity is thought to be a secondary end point of phase I studies. It might be difficult to conclude this answer as unsuitable as screening for anti-tumour activity may be a part of such studies. For example, PSC 833 is targeted to the patients who are potentially resistant to vinca alkaloids or anthracyclines with multidrug resistance (MDR) overexpression. The result of our study, in which about half of patients did not appear to understand the purpose of phase I trials completely, seems similar to the result reported by Daugherty et al (1995) who asked both open-ended and closed questions (Daugherty et al, 1995) . While it is absolutely essential that patients understand the purpose as well as the details of the method and possible risks and benefits of the clinical trials, patients who have incurable cancer may not be receptive to information on the theoretical basis of clinical trials and they are focused more on how these will affect them, not the scientific methodology. In other words, all patients in this study were aware that they were participating in clinical research and almost all understood the major issues of a phase I trial, such as the unknown risks and uncertain benefits, but they may nevertheless have tended to be concemed about the details of method, possible risks and their own benefit rather than theoretical purposes. In general, patients who understand the basic concepts of the treatment tend to be younger and better educated (Daugherty et al, 1995; Cassileth et al, 1980; Lavelle-Jones et al, 1993) . However, in our study, accurate identification of the purpose of a phase I trial did not correlate with educational level and age. Unexpectedly, one-third of our patients thought that their cancer would be cured even although they were given a careful and thorough explanation. There were no statistically significant correlation with age with regard to patients viewing their cancers as curable. Some of these reasons might be the small sample size, the minimal variance in age and education in the present sample and the homogenous nature of Japanese culture and society. The majority of the patients even in phase 11/111 studies are aware of the seriousness of their illness (Penman et al, 1984) . Although the physician's expectation might influence the patient's attitude (Emanuel, 1995) , patients might refuse to accept information they don't wish to hear. Patients' denial of their disease status may understandably obstruct their ability to comprehend information given.
Rodenhuis et al (1984) reported that half of the patients studied were motivated by the hope of improvement of their disease and that 2 of 10 patients believed the treatment to have been effective (Rodenhuis et al, 1984) . In our study, however, only about one-fifth of the patients were motivated to participate because they perceived that the treatment would be of benefit to them. Twenty patients (63%) indicated the response of 'no treatment benefit to myself but wish to participate anyway'. This response may not provide an answer to the question of why patients participated in these studies but suggests that patients wished to try something rather than to do nothing against their cancer. Furthermore, 11 patients (34%) indicated the response of 'The phase I trial might be ineffective, but I would There is inter-institutional variation in opinions and practices regarding patient selection, including that in the USA (Mick et al, 1994) . There seem to be various methods and approaches based on cultural and individual considerations (Willems and Sessa, 1989) in the manner of informing cancer patients about phase I trials. Although much more information is being disclosed to cancer patients than in the past, there is still considerable disagreement and regional differences in Japan about how much information should be conveyed. Although many cancer patients are kept unaware of their diagnosis and treatment, decisions are made relatively independently by their physicians and family members in general hospitals in Japan (Fukaura et al, 1995) , almost all patients who consult physicians in cancer centres are aware of their cancer. In addition, clinical studies in Japan have been improved because of the introduction of the Japanese guidelines for the methodology of clinical evaluation of antineoplastic drugs (Suemasu et al, 1991) . Therefore, it should be kept in mind that the conclusions of this survey cannot be considered to be representative of Japan in general but represent a highly selected population treated in our institution. The results nevertheless suggest that there are no great differences between patients' motivation, comprehension and expectations in phase I trials in our institution and those in Western countries if patients have good levels of information concerning the intent and design of the trials.
We concluded that most patients in phase I trials conducted in our institution were very well informed and made the decision to participate freely. However, about half of the patients did not appear to understand the purpose of the phase I trials completely, and one-third of the patients did not appear to understand that their disease was incurable.
This survey study is the first study concerning the informed consent process in phase I trials. Our survey indicates that methods for more clearly explaining the purpose of clinical trials should be developed. It may be difficult to improve the comprehension of the purpose of phase I trials. The endeavour to promote the spread of general concepts of a clinical trial of cancer chemotherapy would necessitate innovations regarding existing conditions in Japan and international standardization in clinical development of new anticancer agents between Japan and the USA or Europe.
